<DOC>
	<DOCNO>NCT02226861</DOCNO>
	<brief_summary>Background : - Stem cell transplantation partially match donor lead graft-versus-host disease ( GVHD ) . Researchers want learn improve transplantation . Objective : - To see low dos Interleukin-2 partially match transplantation prevent GVHD . Eligibility : - Recipients : age 18 65 , certain bone marrow lymphatic system diseases available family member partial tissue match . - Donors : age 18 80 . Design : - Recipients screen medical history , physical exam , many test include blood tissue tie . - Donors screen medical history , physical exam , blood test tissue type . - Recipients stay hospital 3 6 week . - All participant apheresis . Blood drawn one arm , run machine collect white blood cell , return arm . - Recipients : - Intravenous ( IV ) line place skin neck vein , stay throughout transplant recovery . They may also catheter inserted collect immune cell . - Bone marrow sample take needle . They 3 transplant . - Donors : - Filgrastim inject daily 5 6 day . - Stem immune cell collect another apheresis . - Recipients get : - Eight 30-minute dos radiation , sit machine . - Donor immune cell IV , 6 day transplant day . - Chemotherapy drug IV . &lt; TAB &gt; &lt; TAB &gt; - Donor stem cell IV transplant day . - After transplant , recipient give self-injections low dos Interleukin-2 daily 12 week . - Before transplant , recipient get medicine suppress immune system antibiotic prevent infection - Recipients must stay near NIH 3 6 month transplant . - All recipient donor 3 year follow-up .</brief_summary>
	<brief_title>Ultra-Low Dose IL-2 Therapy GVHD Prophylaxis Haploidentical Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Although allogeneic stem cell transplantation ( allo-SCT ) curative option many hematologic malignancy , suitable donor . Haploidentical peripheral blood stem cell transplantation ( haplo-SCT ) advantage immediate availability , high stem cell dose , feasibility repeat cell collection generate lymphocyte infusion treat prevent relapse infection . However , haplo-SCT incurs risk bidirectional rejection either severe graft versus host disease ( GVHD ) graft rejection recipient . Therefore important develop novel strategy optimize outcome haplo-SCT . Designing haplo-SCT incorporates concept modulate immune system allow opportunity graft manipulation and/or adoptive immunotherapy may improve treatment outcome . To achieve , first interested study immune modulatory effect ultra-low dose Interleukin 2 ( ULD IL-2 ) GVHD prophylaxis . This investigator initiate pilot study determine safety feasibility ULD IL-2 GVHD prophylaxis haploidentical allogeneic stem cell transplantation patient hematologic malignancy . Because GVHD previously associate low number circulate CD4+ CD25+FOXP3+ regulatory T cell ( T ( regs ) ) , research effort increase T ( regs ) either ex-vivo adoptive transfer T ( regs ) vivo use immunomodulatory agent IL-2 , show promise reduce incidence GVHD . The primary objective study evaluate safety feasibility . Secondary objective determine incidence acute chronic GVHD , engraftment , overall survival , transplant related mortality , relapse . We adopt 2 step haplo-SCT method develop Grosso et . al1 study method GVHD prophylaxis . This 2 step approach , lymphoid myeloid portion graft give two separate step order control optimize T-cell , already publish feasible safe platform haplo SCT patient hematologic malignancy adopt Jefferson University Hospital ( PA , USA ) , continue treat patient protocol . As additional GVHD prophylaxis , use sirolimus , previously establish GVHD prophylaxis may work ULD IL-2 synergistically increase T ( regs ) . The haploidentical donor mobilize G-CSF undergo one apheresis collect lymphocytes CD34+ stem cell product Miltenyi CD34+ selection . The product cryopreserved time transplantation . Recipients receive myeloablative conditioning regimen fludarabine total body irradiation ( TBI ) day -10 -6 . After last fraction TBI , donor lymphocyte infusion ( DLI ) product ( 2 time 10 ( 8 ) CD3+/kg ) give . Cyclophosphamide give day -3 -2 , follow CD 34+ select donor stem cell product infuse day 0 . Sirolimus initiate day -1 day+60 . ULD-IL2 ( 100,000 IU/m2 ) give subcutaneously daily 12 week start day +1 . This study evaluate 10 recipient ( age great equal 18 - less equal 70 ; plan accrual 20 recipient event replacement ) hematologic malignancy meet indication transplant match related unrelated donor available . Safety monitor continuously stop rule toxicity base treatment-related serious adverse event rate ( TRSAE ) . Safety monitoring continue least 114 day transplantation , recipient experience adverse event monitor toxicity resolution stabilization . Stopping rule define nonrelapse mortality steroid refractory GVHD period safety monitoring ULD IL-2 . Recipients follow 3 year evaluate incidence acute chronic GVHD , engraftment , overall survival , transplant related mortality , relapse .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>INCLUSION CRITERIA RECIPIENT : Ages 1870 year inclusive Haploidentical donor available Any one follow hematologic condition meet standard indication allogeneic stem cell transplant : Chronic myelogenous leukemia ( CML ) : Subjects age 21 chronic phase OR subject age 1865 chronic phase fail treatment imatinib intolerance imatinib OR Subjects age 1865 accelerate phase blast transformation . OR Acute lymphoblastic leukemia ( ALL ) : category : Adult ALL include standard risk . All second subsequent remission , primary induction failure , partially respond untreated relapse . OR Acute myelogenous leukemia ( AML ) : AML first remission except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , ckit unmutated AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . OR Myelodysplasticsyndromes ( MDS ) : category refractory anemia transfusion dependence , refractory anemia ANC &lt; 500/ ( Micro ) L , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia , atypical MDS/myeloproliferative syndrome . OR Myeloproliferative disorder include atypical ( Phnegative ) chronic myeloid neutrophilic leukemia , progress myelofibrosis , polycythemia vera , essential thrombocythemia either transformation acute leukemia progressive transfusion requirement pancytopenia . OR NonHodgkin lymphoma include Mantle cell lymphoma relapse refractory standard care treatment . OR Multiple myeloma , Waldenstroms macroglobulinemia , unresponsive relapse follow standard care treatment . OR Hodgkin 's Lymphoma relapse follow autologous transplant . OR Other rare hematologic malignancy hematopoietic stem cell transplantation perform offer durable remission option potential cure . Chemotherapyresistant multisystem Langerhans cell histiocytosis ( MSLCH ) especially involve organ like bone marrow , liver , spleen , lung Aggressive systemic mastocytosis , mast cell leukemia ( MCL ) first CR ( CR1 ) Hypereosinophilic syndrome fail imatinib therapy FIP1L1PDGFRanegative patient develop endorgan dysfunction Adult Tcell leukemia/lymphoma first diagnosis Refractory disseminate nasaltype extranodal NK/Tlymphoma aggressive Natural killer cell leukemia/lymphoma Mycosis fungoides S ( SqrRoot ) ( Copyright ) zary syndrome failure two three initial therapy Primary relapse refractory Angioimmunoblastic Tcell lymphoma first diagnosis Hepatosplenic Tcell lymphoma ( gamma/delta Tcell lymphoma ) first diagnosis Tcell prolymphocytic leukemia first diagnosis Subcutaneous panniculitic Tcell lymphoma first diagnosis Hematodermic neoplasm ( blastic natural killer cell lymphoma Blastic plasmacytoid dendritic cell neoplasm ) first diagnosis Ability comprehend investigational nature study provide inform consent . EXCLUSION CRITERIA RECIPIENT ( ANY OF THE FOLLOWING ) : HLA identical ( 6/6 ) relate ( 8/8 allele level match ) unrelated donor available readily accessible time transplantation evaluation Major anticipate illness organ failure incompatible survival transplant Severe psychiatric illness mental deficiency sufficiently severe make compliance transplant treatment unlikely make informed consent impossible . Positive pregnancy test woman childbearing age Contraindication receive IL2 include : Hypersensitivity IL2 Sustained ventricular tachycardia ( &gt; 5 beat ) Cardiac arrhythmia control unresponsive management Chest pain ECG change , consistent angina myocardial infarction Cardiac tamponade Intubation &gt; 72 hour Renal failure require dialysis &gt; 72 hour Coma toxic psychosis last &gt; 48 hour Repetitive difficult control seizures Active bowel ischemia perforation Active GI bleed require surgery DLCO adjust Hb ventilation &lt; 50 % predict Left ventricular ejection fraction &lt; 40 % ( evaluated ECHO ) &lt; 30 % ( evaluated MUGA ) AST/SGOT &gt; 5 time ULN Total bilirubin &gt; 3 time ULN Estimated GFR &lt; 60ml/min ( calculate CKDEPI , formula routinely use Clinical Research Center National Institutes Health . In case borderline estimate GFR , CKDEPI creatininecystatin C formula use accurate estimation ) Prior allogeneic stem cell transplantation INCLUSION CRITERIA DONOR : Related donor share 1 haplotype recipient Age great equal 18 less equal 80 year old Ability comprehend investigational nature study provide inform consent . EXCLUSION CRITERIA DONOR ( ANY OF THE FOLLOWING ) : Unfit receive GCSF undergo apheresis abnormal blood count , history stroke , uncontrolled hypertension Sickling hemaglobinopathy include HbSS , HbAS , HbSC Donors positive HIV , active hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLVI/II ) Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely make informed consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 15, 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
</DOC>